Table 3.
Univariable and multivariable analysis of potential predictive factors of overall survival after relapse
| Variable | Univariable analysis |
Multivariable analysis |
||||
|---|---|---|---|---|---|---|
| P | HR | 95% CI | P | HR | 95% CI | |
| Age (< vs ≥ median of 49 y) | < .001∗ | 0.529 | 0.384-0.729 | .006∗ | 0.588 | 0.404-0.857 |
| Sex (female vs male) | .298 | 0.842 | 0.610-1.163 | |||
| KPS (≥ vs < median of 70%) | < .001∗ | 0.366 | 0.255-0.525 | < .001∗ | 0.366 | 0.246-0.543 |
| MGMT-status (methylated vs unmethylated) | .559 | 0.778 | 0.336-1.804 | |||
| Grading (3 vs 4) | .001∗ | 0.522 | 0.351-0.776 | .287 | 0.789 | 0.509-1.221 |
| Surgery (gross total resection vs no surgery/biopsy/subtotal resection) | .6 | 1.094 | 0.782-1.531 | |||
| Interval from initial RT to reirradiation (≥14 vs <14) | .269 | 0.835 | 0.606-1.15 | |||
| PTV (≥ vs < median of 46.25 ccm) | .721 | 1.062 | 0.763-1.479 | |||
| Fractionation schema (accelerated hyperfractionation vs normofractionation/hypofractionation) | .876 | 1.045 | 0.602-1.815 | |||
| BED to tumor (≥ vs < median of 58.8 Gy) | .02∗ | 0.685 | 0.498-0.943 | .201 | 0.785 | 0.541-1.138 |
| Chemotherapy at recurrence (yes vs no) | .991 | 0.998 | 0.726-1.372 | |||
| Nanotherapy (yes vs no) | .256 | 1.324 | 0.816-2.148 | |||
Abbreviations: BED = biologically effective dose; CI = confidence interval; HR = hazard ratio; KPS = Karnofsky performance status; MGMT = O-6-methylguanine-DNA methyltransferase; PTV = planning target volume.
∗
P value ≤ .05.